Maxim Group Lowers Femasys (NASDAQ:FEMY) Price Target to $10.00

Femasys (NASDAQ:FEMY) had its price objective decreased by Maxim Group from $30.00 to $10.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 336.68% from the stock’s previous close.

Several other brokerages have also recently issued reports on FEMY. Weiss Ratings upgraded shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Femasys to a “hold” rating in a report on Saturday, June 13th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.67.

Femasys Stock Performance

NASDAQ FEMY remained flat at $2.29 during trading on Friday. 113,658 shares of the company’s stock traded hands, compared to its average volume of 63,992. The stock has a 50 day simple moving average of $3.67 and a two-hundred day simple moving average of $7.35. Femasys has a 1-year low of $2.19 and a 1-year high of $22.20. The company has a current ratio of 3.91, a quick ratio of 1.98 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $6.92 million, a P/E ratio of -0.42 and a beta of -2.08.

Insiders Place Their Bets

In related news, CFO Dov Elefant purchased 15,625 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $3.20 per share, for a total transaction of $50,000.00. Following the purchase, the chief financial officer directly owned 15,625 shares of the company’s stock, valued at approximately $50,000. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kathy Lee-Sepsick bought 15,625 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief executive officer owned 15,625 shares of the company’s stock, valued at approximately $50,000. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have bought 38,750 shares of company stock worth $124,000. Company insiders own 7.75% of the company’s stock.

Institutional Trading of Femasys

Several institutional investors have recently bought and sold shares of FEMY. State Street Corp grew its position in Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares during the last quarter. Kovack Advisors Inc. purchased a new position in Femasys in the fourth quarter worth about $27,000. Osaic Holdings Inc. bought a new position in shares of Femasys in the second quarter worth approximately $45,000. HRT Financial LP bought a new position in shares of Femasys in the fourth quarter worth approximately $30,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Femasys during the fourth quarter valued at approximately $36,000. 65.27% of the stock is owned by hedge funds and other institutional investors.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.